{"pmid":32324359,"title":"[Diagnostic steps and estimation of disease prognosis in COVID-19-infected patients].","text":["[Diagnostic steps and estimation of disease prognosis in COVID-19-infected patients].","In December 2019, a new coronavirus outbreak hit his head in Wuhan, China. The identified pathogen is a new coronavirus named \"severe acute respiratory syndrome coronavirus 2,\" or SARS-CoV-2, and the respiratory syndrome it elicits was named \"coronavirus disease 2019,\" or COVID-19. The World Health Organization (WHO) classified the epidemic as a pandemic in March 2020. We reviewed the currently available international literature on the COVID-19 epidemic. In this paper, we summarize the relevant information for the diagnosis and prognosis of the new coronavirus. Details of the anamnestic factors and initial test results required to raise a clinical suspicion, the method of microbiological sampling, the basic information on the molecular diagnostic test - the 'gold-standard' real-time 'reverse transcriptase polymerase chain reaction (RT-PCR) - in particular the diagnostic current public health regulations for testing. We also place emphasis on the parameters of high-risk patients and how to identify them. The COVID-19 pandemic may also have significant epidemiological and health consequences in Hungary. In addition to epidemiological measures to slow down the epidemic, the timely identification and adequate hospital care of already infected individuals is also a key issue in terms of mortality. The chances of critically ill patients can only be improved with high-quality, careful intensive care, and to be able to provide the best, it is useful to use the experience of medical colleagues already working in endemic countries. Orv Hetil. 2020; 160 (17): 667-671.","Orv Hetil","Korsos, Anita","Kupcsulik, Szilvia","Lovas, Andras","Hankovszky, Peter","Molnar, Tamas","Szabo, Zsolt","Babik, Barna","32324359"],"abstract":["In December 2019, a new coronavirus outbreak hit his head in Wuhan, China. The identified pathogen is a new coronavirus named \"severe acute respiratory syndrome coronavirus 2,\" or SARS-CoV-2, and the respiratory syndrome it elicits was named \"coronavirus disease 2019,\" or COVID-19. The World Health Organization (WHO) classified the epidemic as a pandemic in March 2020. We reviewed the currently available international literature on the COVID-19 epidemic. In this paper, we summarize the relevant information for the diagnosis and prognosis of the new coronavirus. Details of the anamnestic factors and initial test results required to raise a clinical suspicion, the method of microbiological sampling, the basic information on the molecular diagnostic test - the 'gold-standard' real-time 'reverse transcriptase polymerase chain reaction (RT-PCR) - in particular the diagnostic current public health regulations for testing. We also place emphasis on the parameters of high-risk patients and how to identify them. The COVID-19 pandemic may also have significant epidemiological and health consequences in Hungary. In addition to epidemiological measures to slow down the epidemic, the timely identification and adequate hospital care of already infected individuals is also a key issue in terms of mortality. The chances of critically ill patients can only be improved with high-quality, careful intensive care, and to be able to provide the best, it is useful to use the experience of medical colleagues already working in endemic countries. Orv Hetil. 2020; 160 (17): 667-671."],"journal":"Orv Hetil","authors":["Korsos, Anita","Kupcsulik, Szilvia","Lovas, Andras","Hankovszky, Peter","Molnar, Tamas","Szabo, Zsolt","Babik, Barna"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32324359","week":"202017|Apr 20 - Apr 26","doi":"10.1556/650.2020.31815","keywords":["covid-19","rt-pcr","sars-cov-2","diagnostic testing high-risk patient","diagnosztika","jarvany","magas rizikoju beteg","novel coronavirus","outbreak","pandemic","pandemia","prognosis","prognozis","uj koronavirus"],"source":"PubMed","topics":["Diagnosis","Treatment"],"weight":1,"locations":["Wuhan","China","Hungary"],"countries":["China","Hungary"],"countries_codes":["CHN|China","HUN|Hungary"],"_version_":1664895932644196352,"score":8.518259,"similar":[{"pmid":32219885,"title":"Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19.","text":["Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19.","In this study, we collected a total of 610 hospitalized patients from Wuhan between February 2, 2020, and February 17, 2020. We reported a potentially high false negative rate of real-time reverse-transcriptase polymerase chain reaction (RT-PCR) testing for SARS-CoV-2 in the 610 hospitalized patients clinically diagnosed with COVID-19 during the 2019 outbreak. We also found that the RT-PCR results from several tests at different points were variable from the same patients during the course of diagnosis and treatment of these patients. Our results indicate that in addition to the emphasis on RT-PCR testing, clinical indicators such as computed tomography images should also be used not only for diagnosis and treatment but also for isolation, recovery/discharge, and transferring for hospitalized patients clinically diagnosed with COVID-19 during the current epidemic. These results suggested the urgent needs for the standard of procedures of sampling from different anatomic sites, sample transportation, optimization of RT-PCR, serology diagnosis/screening for SARS-CoV-2 infection, and distinct diagnosis from other respiratory diseases such as fluenza infections as well.","J Med Virol","Li, Yafang","Yao, Lin","Li, Jiawei","Chen, Lei","Song, Yiyan","Cai, Zhifang","Yang, Chunhua","32219885"],"abstract":["In this study, we collected a total of 610 hospitalized patients from Wuhan between February 2, 2020, and February 17, 2020. We reported a potentially high false negative rate of real-time reverse-transcriptase polymerase chain reaction (RT-PCR) testing for SARS-CoV-2 in the 610 hospitalized patients clinically diagnosed with COVID-19 during the 2019 outbreak. We also found that the RT-PCR results from several tests at different points were variable from the same patients during the course of diagnosis and treatment of these patients. Our results indicate that in addition to the emphasis on RT-PCR testing, clinical indicators such as computed tomography images should also be used not only for diagnosis and treatment but also for isolation, recovery/discharge, and transferring for hospitalized patients clinically diagnosed with COVID-19 during the current epidemic. These results suggested the urgent needs for the standard of procedures of sampling from different anatomic sites, sample transportation, optimization of RT-PCR, serology diagnosis/screening for SARS-CoV-2 infection, and distinct diagnosis from other respiratory diseases such as fluenza infections as well."],"journal":"J Med Virol","authors":["Li, Yafang","Yao, Lin","Li, Jiawei","Chen, Lei","Song, Yiyan","Cai, Zhifang","Yang, Chunhua"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32219885","week":"202013|Mar 23 - Mar 29","doi":"10.1002/jmv.25786","keywords":["covid-19","rt-pcr"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"locations":["Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664638742955032576,"score":191.0567},{"pmid":32172228,"title":"Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19).","text":["Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19).","A novel zoonotic coronavirus outbreak is spreading all over the world. This pandemic disease has now been defined as novel coronavirus disease 2019 (COVID-19), and is sustained by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As the current gold standard for the etiological diagnosis of SARS-CoV-2 infection is (real time) reverse transcription polymerase chain reaction (rRT-PCR) on respiratory tract specimens, the diagnostic accuracy of this technique shall be considered a foremost prerequisite. Overall, potential RT-PCR vulnerabilities include general preanalytical issues such as identification problems, inadequate procedures for collection, handling, transport and storage of the swabs, collection of inappropriate or inadequate material (for quality or volume), presence of interfering substances, manual errors, as well as specific aspects such as sample contamination and testing patients receiving antiretroviral therapy. Some analytical problems may also contribute to jeopardize the diagnostic accuracy, including testing outside the diagnostic window, active viral recombination, use of inadequately validated assays, insufficient harmonization, instrument malfunctioning, along with other specific technical issues. Some practical indications can hence be identified for minimizing the risk of diagnostic errors, encompassing the improvement of diagnostic accuracy by combining clinical evidence with results of chest computed tomography (CT) and RT-PCR, interpretation of RT-PCR results according to epidemiologic, clinical and radiological factors, recollection and testing of upper (or lower) respiratory specimens in patients with negative RT-PCR test results and high suspicion or probability of infection, dissemination of clear instructions for specimen (especially swab) collection, management and storage, together with refinement of molecular target(s) and thorough compliance with analytical procedures, including quality assurance.","Clin Chem Lab Med","Lippi, Giuseppe","Simundic, Ana-Maria","Plebani, Mario","32172228"],"abstract":["A novel zoonotic coronavirus outbreak is spreading all over the world. This pandemic disease has now been defined as novel coronavirus disease 2019 (COVID-19), and is sustained by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As the current gold standard for the etiological diagnosis of SARS-CoV-2 infection is (real time) reverse transcription polymerase chain reaction (rRT-PCR) on respiratory tract specimens, the diagnostic accuracy of this technique shall be considered a foremost prerequisite. Overall, potential RT-PCR vulnerabilities include general preanalytical issues such as identification problems, inadequate procedures for collection, handling, transport and storage of the swabs, collection of inappropriate or inadequate material (for quality or volume), presence of interfering substances, manual errors, as well as specific aspects such as sample contamination and testing patients receiving antiretroviral therapy. Some analytical problems may also contribute to jeopardize the diagnostic accuracy, including testing outside the diagnostic window, active viral recombination, use of inadequately validated assays, insufficient harmonization, instrument malfunctioning, along with other specific technical issues. Some practical indications can hence be identified for minimizing the risk of diagnostic errors, encompassing the improvement of diagnostic accuracy by combining clinical evidence with results of chest computed tomography (CT) and RT-PCR, interpretation of RT-PCR results according to epidemiologic, clinical and radiological factors, recollection and testing of upper (or lower) respiratory specimens in patients with negative RT-PCR test results and high suspicion or probability of infection, dissemination of clear instructions for specimen (especially swab) collection, management and storage, together with refinement of molecular target(s) and thorough compliance with analytical procedures, including quality assurance."],"journal":"Clin Chem Lab Med","authors":["Lippi, Giuseppe","Simundic, Ana-Maria","Plebani, Mario"],"date":"2020-03-16T11:00:00Z","year":2020,"_id":"32172228","week":"202012|Mar 16 - Mar 22","doi":"10.1515/cclm-2020-0285","keywords":["covid-19","coronavirus","diagnosis","reverse transcription polymerase chain reaction (rt-pcr)"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1664640874673340418,"score":182.18277},{"pmid":32174053,"pmcid":"PMC7082661","title":"False-Negative Results of Real-Time Reverse-Transcriptase Polymerase Chain Reaction for Severe Acute Respiratory Syndrome Coronavirus 2: Role of Deep-Learning-Based CT Diagnosis and Insights from Two Cases.","text":["False-Negative Results of Real-Time Reverse-Transcriptase Polymerase Chain Reaction for Severe Acute Respiratory Syndrome Coronavirus 2: Role of Deep-Learning-Based CT Diagnosis and Insights from Two Cases.","The epidemic of 2019 novel coronavirus, later named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is still gradually spreading worldwide. The nucleic acid test or genetic sequencing serves as the gold standard method for confirmation of infection, yet several recent studies have reported false-negative results of real-time reverse-transcriptase polymerase chain reaction (rRT-PCR). Here, we report two representative false-negative cases and discuss the supplementary role of clinical data with rRT-PCR, including laboratory examination results and computed tomography features. Coinfection with SARS-COV-2 and other viruses has been discussed as well.","Korean J Radiol","Li, Dasheng","Wang, Dawei","Dong, Jianping","Wang, Nana","Huang, He","Xu, Haiwang","Xia, Chen","32174053"],"abstract":["The epidemic of 2019 novel coronavirus, later named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is still gradually spreading worldwide. The nucleic acid test or genetic sequencing serves as the gold standard method for confirmation of infection, yet several recent studies have reported false-negative results of real-time reverse-transcriptase polymerase chain reaction (rRT-PCR). Here, we report two representative false-negative cases and discuss the supplementary role of clinical data with rRT-PCR, including laboratory examination results and computed tomography features. Coinfection with SARS-COV-2 and other viruses has been discussed as well."],"journal":"Korean J Radiol","authors":["Li, Dasheng","Wang, Dawei","Dong, Jianping","Wang, Nana","Huang, He","Xu, Haiwang","Xia, Chen"],"date":"2020-03-17T11:00:00Z","year":2020,"_id":"32174053","week":"202012|Mar 16 - Mar 22","doi":"10.3348/kjr.2020.0146","keywords":["covid-19","computed tomography","false-negative results","laboratory examination","sars-cov-2","rrt-pcr"],"link_erratum_in":"32207257","source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1664640874653417472,"score":161.38103},{"pmid":32110875,"pmcid":"PMC7141113","title":"Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review.","text":["Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review.","Rapid diagnostics, vaccines and therapeutics are important interventions for the management of the 2019 novel coronavirus (2019-nCoV) outbreak. It is timely to systematically review the potential of these interventions, including those for Middle East respiratory syndrome-Coronavirus (MERS-CoV) and severe acute respiratory syndrome (SARS)-CoV, to guide policymakers globally on their prioritization of resources for research and development. A systematic search was carried out in three major electronic databases (PubMed, Embase and Cochrane Library) to identify published studies in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Supplementary strategies through Google Search and personal communications were used. A total of 27 studies fulfilled the criteria for review. Several laboratory protocols for confirmation of suspected 2019-nCoV cases using real-time reverse transcription polymerase chain reaction (RT-PCR) have been published. A commercial RT-PCR kit developed by the Beijing Genomic Institute is currently widely used in China and likely in Asia. However, serological assays as well as point-of-care testing kits have not been developed but are likely in the near future. Several vaccine candidates are in the pipeline. The likely earliest Phase 1 vaccine trial is a synthetic DNA-based candidate. A number of novel compounds as well as therapeutics licensed for other conditions appear to have in vitro efficacy against the 2019-nCoV. Some are being tested in clinical trials against MERS-CoV and SARS-CoV, while others have been listed for clinical trials against 2019-nCoV. However, there are currently no effective specific antivirals or drug combinations supported by high-level evidence.","J Clin Med","Pang, Junxiong","Wang, Min Xian","Ang, Ian Yi Han","Tan, Sharon Hui Xuan","Lewis, Ruth Frances","Chen, Jacinta I-Pei","Gutierrez, Ramona A","Gwee, Sylvia Xiao Wei","Chua, Pearleen Ee Yong","Yang, Qian","Ng, Xian Yi","Yap, Rowena Ks","Tan, Hao Yi","Teo, Yik Ying","Tan, Chorh Chuan","Cook, Alex R","Yap, Jason Chin-Huat","Hsu, Li Yang","32110875"],"abstract":["Rapid diagnostics, vaccines and therapeutics are important interventions for the management of the 2019 novel coronavirus (2019-nCoV) outbreak. It is timely to systematically review the potential of these interventions, including those for Middle East respiratory syndrome-Coronavirus (MERS-CoV) and severe acute respiratory syndrome (SARS)-CoV, to guide policymakers globally on their prioritization of resources for research and development. A systematic search was carried out in three major electronic databases (PubMed, Embase and Cochrane Library) to identify published studies in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Supplementary strategies through Google Search and personal communications were used. A total of 27 studies fulfilled the criteria for review. Several laboratory protocols for confirmation of suspected 2019-nCoV cases using real-time reverse transcription polymerase chain reaction (RT-PCR) have been published. A commercial RT-PCR kit developed by the Beijing Genomic Institute is currently widely used in China and likely in Asia. However, serological assays as well as point-of-care testing kits have not been developed but are likely in the near future. Several vaccine candidates are in the pipeline. The likely earliest Phase 1 vaccine trial is a synthetic DNA-based candidate. A number of novel compounds as well as therapeutics licensed for other conditions appear to have in vitro efficacy against the 2019-nCoV. Some are being tested in clinical trials against MERS-CoV and SARS-CoV, while others have been listed for clinical trials against 2019-nCoV. However, there are currently no effective specific antivirals or drug combinations supported by high-level evidence."],"journal":"J Clin Med","authors":["Pang, Junxiong","Wang, Min Xian","Ang, Ian Yi Han","Tan, Sharon Hui Xuan","Lewis, Ruth Frances","Chen, Jacinta I-Pei","Gutierrez, Ramona A","Gwee, Sylvia Xiao Wei","Chua, Pearleen Ee Yong","Yang, Qian","Ng, Xian Yi","Yap, Rowena Ks","Tan, Hao Yi","Teo, Yik Ying","Tan, Chorh Chuan","Cook, Alex R","Yap, Jason Chin-Huat","Hsu, Li Yang"],"date":"2020-03-01T11:00:00Z","year":2020,"_id":"32110875","week":"20209|Feb 24 - Mar 01","doi":"10.3390/jcm9030623","keywords":["mers-cov","sars-cov","diagnostics","global health","novel coronavirus","outbreak","treatments","vaccine"],"source":"PubMed","topics":["Treatment","Diagnosis"],"weight":1,"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664640875088576512,"score":154.41747},{"pmid":32292623,"pmcid":"PMC7102540","title":"Recent advances and perspectives of nucleic acid detection for coronavirus.","text":["Recent advances and perspectives of nucleic acid detection for coronavirus.","The recent pneumonia outbreak caused by a novel coronavirus (SARS-CoV-2) in Chinais posing a great threat to global public health. Therefore, rapid and a accurate identification of pathogenic viruses plays a vital role in selecting appropriate treatments, saving people's lives and preventing epidemics. It is important to establish a quick standard diagnostic test for the detection of the infectious disease (COVID-19) to prevent subsequent secondary spread. Polymerase chain reaction (PCR) is regarded as a gold standard test for the molecular diagnosis of viral and bacterial infections with high sensitivity and specificity. Isothermal nucleic acid amplification is considered to be a highly promising candidate method due to its fundamental advantage in quick procedure time at constant temperature without thermocycler operation. A variety of improved or new approaches also have been developed. This review summarizes the currently available detection methods for coronavirus nucleic acid. It is anticipated that this will assist researchers and clinicians in developing better techniques for timely and effective detection of coronavirus infection.","J Pharm Anal","Shen, Minzhe","Zhou, Ying","Ye, Jiawei","Abdullah Al-Maskri, Abdu Ahmed","Kang, Yu","Zeng, Su","Cai, Sheng","32292623"],"abstract":["The recent pneumonia outbreak caused by a novel coronavirus (SARS-CoV-2) in Chinais posing a great threat to global public health. Therefore, rapid and a accurate identification of pathogenic viruses plays a vital role in selecting appropriate treatments, saving people's lives and preventing epidemics. It is important to establish a quick standard diagnostic test for the detection of the infectious disease (COVID-19) to prevent subsequent secondary spread. Polymerase chain reaction (PCR) is regarded as a gold standard test for the molecular diagnosis of viral and bacterial infections with high sensitivity and specificity. Isothermal nucleic acid amplification is considered to be a highly promising candidate method due to its fundamental advantage in quick procedure time at constant temperature without thermocycler operation. A variety of improved or new approaches also have been developed. This review summarizes the currently available detection methods for coronavirus nucleic acid. It is anticipated that this will assist researchers and clinicians in developing better techniques for timely and effective detection of coronavirus infection."],"journal":"J Pharm Anal","authors":["Shen, Minzhe","Zhou, Ying","Ye, Jiawei","Abdullah Al-Maskri, Abdu Ahmed","Kang, Yu","Zeng, Su","Cai, Sheng"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32292623","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jpha.2020.02.010","keywords":["coronavirus","isothermal nucleic acid amplification-based methods","microarray-based methods","nucleic acid detection","pcr-based methods"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1664636192655671296,"score":152.23097}]}